Anavex Life Sciences Provides an Update on Rett Syndrome Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
Anavex Life Sciences (AVXL) Slumps 38% After Study in Pediatric Rett Syndrome Fails
January 2, 2024 8:17 AM EST(Updated - January 2, 2024 8:21 AM EST)
Anavex Life Sciences (NASDAQ: AVXL) Slumps 38% After Study in Pediatric Rett Syndrome Fails
In an ad-hoc analysis, using the predefined mixed-effect model for repeated measure (MMRM) method, after 12 weeks of treatment, ANAVEX®2-73-treated patients... More